Effects of Lactobacillus Plantarum PS128 on the Parkinsonian Symptoms in Parkinson's Disease.
NCT ID: NCT04722211
Last Updated: 2021-01-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
120 participants
INTERVENTIONAL
2020-07-06
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Lactobacillus Plantarum PS128 on Symptoms of Early-onset Parkinson's Disease: a Pilot Study
NCT04722198
Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson's Disease
NCT03242499
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
NCT01227265
Effect of Synbiotic as an Adjuvant Therapy in the Treatment of Parkinson's Disease
NCT05576818
Levodopa Response and Gut Microbiome in Patients With Parkinson's Disease
NCT04956939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PS128
Each PS128 capsule contained \>1 × 10\^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg
PS128
daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
placebo
The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose
placebo
daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PS128
daily ingestion of 2 capsules of Lactobacillus plantarum PS128 (\>10 billion CFU/capsule)
placebo
daily ingestion of 2 capsules which only contained 425 ± 25 mg microcrystalline cellulose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 45-80 years old
* at least 9 years education
Exclusion Criteria
* Patients using of other probiotic products (sachet, capsule or tablet) within the preceding two weeks
* Have undergone surgery of liver, bladder, or gastrointestinal tract
* Have current or history of inflammatory bowel disease
* Have history of cancer
* Known allergy to probiotics
* Patients with comorbid dementia (Mini-Mental State Examination score ≤ 26) or major depression (The Beck Depression Inventory-II score ≥ 29)
* Have received deep brain stimulation
* Patients receiving artificial enteral or intravenous nutrition
* Diagnosed before 40 years old
* Poor control of other chronic diseases
* Not eligible judged by PI
45 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Professor Lu Neurological Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CHIN-SONG LU
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Professor Lu Neurological Clinic
Taoyuan, Guishan Dist., Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PS128-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.